|
 Lilly said on Monday the new version would be called Insulin Lispro,
while Humalog would remain available for patients who want to
continue accessing it through their current insurance plans.
The news comes as the U.S. government intensifies its scrutiny of
the pharmaceutical industry and rising U.S. prescription drug
prices, a top voter concern and a priority of President Donald
Trump's administration.
The cost of insulin for treating type 1 diabetes in the United
States nearly doubled over a five-year period, underscoring a
national outcry over rising drug prices, Reuters reported in
January.
"We've engaged in discussions about the price of insulin with many
different stakeholders ... people living with diabetes, caregivers,
advocacy groups, health care professionals, payers, wholesalers,
lawmakers," Lilly's Chief Executive Officer David Ricks said in a
statement.
[to top of second column] |
The list price of one vial of Insulin Lispro would be $137.35, Lilly
said. The list price of a drug is not necessarily what patients
actually pay. "Out-of-pocket" costs vary based on the duration of
the treatment and individual healthcare plans.
(Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin
Ravikumar)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
